

Enhancing Public & Private Financing

ShapingBio Summit

25 June 2025, Brussels





ShapingBio BEF Analysis





Bioeconomy financing analysis (BEF) - Methodology ShapingBio

Objective: analyse the opportunities and challenges of private and public financing for companies in the EU bioeconomy.



BEF Analysis - Public Financing - EU level



Received funding CL6 HE



Received funding CL6 HE – innovation groups

Rest



unded by the uropean Unior

4

BEF Analysis - Public Financing, national & regional level 🐼 ShapingBio



Funded by the European Unic



BEF Analysis - Private Financing - early stage







6

BEF Analysis - Private Financing - investors' HQ



Investors in the EU bioeconomy – by financing amounts



BEF Analysis – key findings



Commercialisation bottlenecks

Limited support for business modelling, investor matchmaking, IP transfer, and other soft infrastructure critical to scaling innovations; stakeholders unfamiliar with financing/de-risking opportunities PPP

Funding design gaps

Emphasis on short-term KPIs, insufficient funding per project, limiting support for commercialisation costly scale-up phases (e.g., pilot plants, FOAK facilities).

Regulatory complexity

Complex regulatory landscape limiting market entry, strains SME scaling capacity and hinders investment (higher risk for new products compared with fossil-based)